Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer

被引：4
|
作者：
Morganti, Stefania [1 ,2 ,3 ,4 ,5 ]
Tolaney, Sara M. [1 ,2 ,6 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[2] Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA USA
[3] Harvard Med Sch, Boston, MA USA
[4] Broad Inst & Harvard, Boston, MA USA
[5] Univ Milan, Ist Europeo Oncol, Dept Oncol & Hemato Oncol, Milan, Italy
[6] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2023年 / 37卷 / 01期
关键词：
TNBC; Breast cancer; Immunotherapy; Biomarkers; PDL1; Immune checkpoint inhibitors; PEMBROLIZUMAB PLUS CHEMOTHERAPY; PHASE-III TRIAL; NEOADJUVANT CHEMOTHERAPY; DOUBLE-BLIND; PLACEBO; ATEZOLIZUMAB; PACLITAXEL; MELANOMA; TNBC;
D O I：
10.1016/j.hoc.2022.08.014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：133 / 150
页数：18
相关论文
共 50 条
  • [41] Immunotherapy in Triple-Negative Breast Cancer: Present and Future
    Isaac Kim
    Katherine Sanchez
    Heather L. McArthur
    David Page
    Current Breast Cancer Reports, 2019, 11 : 259 - 271
  • [42] Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
    Luo, Chenyi
    Wang, Peipei
    He, Siqi
    Zhu, Jingjing
    Shi, Yuanyuan
    Wang, Jianxun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] Tumor microenvironment and immunotherapy for triple-negative breast cancer
    Zijie Guo
    Ziyu Zhu
    Xixi Lin
    Shenkangle Wang
    Yihong Wen
    Linbo Wang
    Lili Zhi
    Jichun Zhou
    Biomarker Research, 12 (1)
  • [44] The clinical promise of immunotherapy in triple-negative breast cancer
    Vikas, Praveen
    Borcherding, Nicholas
    Zhang, Weizhou
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6823 - 6833
  • [45] Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
    Julia Dixon-Douglas
    Sherene Loi
    Current Treatment Options in Oncology, 2023, 24 : 1004 - 1020
  • [46] Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
    Dixon-Douglas, Julia
    Loi, Sherene
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (08) : 1004 - 1020
  • [47] Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations
    Santa-Maria, Cesar A.
    O'Donnell, Maureen
    Nunes, Raquel
    Wright, Jean L.
    Stearns, Vered
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (07): : 738 - 744
  • [48] Pembrolizumab for Early Triple-Negative Breast Cancer
    Schmid, Peter
    Cortes, Javier
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Bergh, Jonas
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Foukakis, Theodoros
    Fasching, Peter A.
    Cardoso, Fatima
    Untch, Michael
    Jia, Liyi
    Karantza, Vassiliki
    Zhao, Jing
    Aktan, Gursel
    Dent, Rebecca
    O'Shaughnessy, Joyce
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 810 - 821
  • [49] Pembrolizumab for Early Triple-Negative Breast Cancer
    Cetin, Bulent
    Gumusay, Ozge
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (26):
  • [50] Reversibly Stabilized Polycation Nanoparticles for Combination Treatment of Early- and Late-Stage Metastatic Breast Cancer
    Chen, Gang
    Wang, Yixin
    Wu, Pengkai
    Zhou, Yiwen
    Yu, Fei
    Zhu, Chenfei
    Li, Zhaoting
    Hang, Yu
    Wang, Kaikai
    Li, Jing
    Sun, Minjie
    Oupicky, David
    ACS NANO, 2018, 12 (07) : 6620 - 6636
12345